Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Novel MS Drug Offers Good Functional Outcomes
Pharmacology and therapeutic potential of interferons.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
New multiple sclerosis phenotypic classification.
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
One can prevent post-partum MS relapses by exclusive breast feeding: no.
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
A full genome search in multiple sclerosis.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.

Pages